AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35640658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian AUC48-72
Number of subjects: 65
Study 35640658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian AUC72-96
Number of subjects: 65
Study 35640658 — intervention group
Group type: COMPARATOR
Intervention: First-order pharmacokinetic equation methods
Number of subjects: 65
Study 34337527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigtail suture stent (PSS)
Number of subjects: 78
Study 34337527 — intervention group
Group type: COMPARATOR
Intervention: Conventional double J stent (DJ)
Number of subjects: 78
Study 33960006 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Number of subjects: 60
Study 33960006 — intervention group
Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS) with cognitive processing therapy (CPT+A)
Number of subjects: 60
Study 33408364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lab4P probiotic (50 billion cfu/day)
Number of subjects: 70
Study 33408364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36135352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-based paste applied on 2 MIH teeth in one random quadrant (test group)
Number of subjects: 25
Study 36135352 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 contralateral MIH teeth did not undergo paste application)
Number of subjects: 25
Study 33451345 — intervention group
Group type: EXPERIMENTAL
Intervention: xentuzumab/everolimus/exemestane
Number of subjects: 140
Study 33451345 — intervention group
Group type: COMPARATOR
Intervention: everolimus/exemestane
Number of subjects: 140
Study 33451345 — intervention group
Group type: EXPERIMENTAL
Intervention: xentuzumab/everolimus/exemestane (subgroup without visceral metastases)
Number of subjects: 140
Study 33451345 — intervention group
Group type: COMPARATOR
Intervention: everolimus/exemestane (subgroup without visceral metastases)
Number of subjects: 140
Study 32871327 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI strategy
Number of subjects: 2000
Study 32871327 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI strategy
Number of subjects: 2000
Study 35962199 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy with systematic myocardial revascularization
Number of subjects: 0
Study 35962199 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (anti-tumor necrosis factor antibody)
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of mesenchymal donor stem cells
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and/or seton drainage
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategies (fistulotomy, disconnection of the fistula, filling of the fistula tract, fistula ablation)
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal physiotherapy
Number of subjects: 0
Study 34704480 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy directed against intestinal inflammation
Number of subjects: 0
Study 34890827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) with a daily maintenance dose of 3900 mg
Number of subjects: 12
Study 34890827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) during maintenance
Number of subjects: 12
Study 34890827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) after 1 month of treatment discontinuation
Number of subjects: 12
Study 34890827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) after 12 months
Number of subjects: 12
Study 34639642 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR) intervention
Number of subjects: 7350
Study 34639642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PHR)
Number of subjects: 7350
Study 32459070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac withdrawal
Number of subjects: 14
Study 32459070 — intervention group
Group type: COMPARATOR
Intervention: Tac maintenance
Number of subjects: 14
Study 33159422 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 146
Study 33159422 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control (progressive muscle relaxation)
Number of subjects: 146
Study 35481712 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily for 3 months
Number of subjects: 228
Study 35481712 — intervention group
Group type: COMPARATOR
Intervention: conventional treatment (warfarin or rivaroxaban)
Number of subjects: 228
Study 35130214 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clotrimazole ear drops
Number of subjects: 120
Study 35130214 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% salicylic acid drops
Number of subjects: 120
Study 35130214 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine drops
Number of subjects: 120
Study 35130214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 120
Study 35091463 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 203
Study 35091463 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 203
Study 32807659 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver barrel contact lens storage cases
Number of subjects: 48
Study 32807659 — intervention group
Group type: COMPARATOR
Intervention: Non-silver (control) barrel contact lens storage cases
Number of subjects: 48
Study 32807659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel lenses in combination with silver cases
Number of subjects: 48
Study 32807659 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance score
Number of subjects: 48
Study 35709245 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Muscle Relaxation (APMR)
Number of subjects: 114
Study 35709245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Breathing (MB)
Number of subjects: 114
Study 35709245 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring (SM)
Number of subjects: 114
Study 32627420 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 798
Number of subjects: 0
Study 32627420 — intervention group
Group type: COMPARATOR
Intervention: Rituximab RP (US and EU sourced)
Number of subjects: 0
Study 36216624 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction treatment (4 first premolars removed)
Number of subjects: 60
Study 36216624 — intervention group
Group type: COMPARATOR
Intervention: Nonextraction treatment
Number of subjects: 60
Study 36216624 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction treatment with minimal lip strain
Number of subjects: 60
Study 36216624 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction treatment
Number of subjects: 60
Study 35662502 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic‐cell vaccine therapy combined with systemic therapy
Number of subjects: 0
Study 35662502 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 35662502 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32631388 — intervention group
Group type: EXPERIMENTAL
Intervention: AHE (Allium hookeri extract) 486 mg/day
Number of subjects: 30
Study 32631388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36318499 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative writing intervention with resources and support from a narrative medicine facilitator
Number of subjects: 0
Study 36318499 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative thematic analysis of written texts
Number of subjects: 0
Study 34731574 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation group treatment (1 hr, twice per week, for 10 weeks)
Number of subjects: 48
Study 34731574 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 34731574 — intervention group
Group type: COMPARATOR
Intervention: Treated groups and Control group
Number of subjects: 48
Study 32888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with wastewater (source not specified)
Number of subjects: 5
Study 32888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with varied water sources (three sources)
Number of subjects: 5
Study 32888150 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioaccumulation, translocation, bio-concentration, daily intake, and enrichment values of cadmium
Number of subjects: 5
Study 33878429 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS applied at high vigilance
Number of subjects: 16
Study 33878429 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS applied at low vigilance
Number of subjects: 16
Study 33878429 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS applied at a random moment
Number of subjects: 16
Study 32147071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical henna preparation applied every night for two weeks
Number of subjects: 95
Study 32147071 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 95
Study 36315457 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical-grade honey (MGH) applied intra-socket (L-Mesitran Soft)
Number of subjects: 21
Study 36315457 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment applied)
Number of subjects: 21
Study 33494622 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-LASIK
Number of subjects: 165
Study 33494622 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 165
Study 32501985 — intervention group
Group type: COMPARATOR
Intervention: High-dose tirofiban (20 μg/kg)
Number of subjects: 312
Study 32501985 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose tirofiban (10 μg/kg)
Number of subjects: 312
Study 35389229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35886120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit with US smartphone application
Number of subjects: 273
Study 35886120 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacists’ smoking cessation counseling only)
Number of subjects: 273
Study 33116073 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapula training exercises
Number of subjects: 46
Study 33116073 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic exercise and physical therapy
Number of subjects: 46
Study 36006034 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (100 mg)
Number of subjects: 10
Study 36006034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg lactose powder)
Number of subjects: 10
Study 33160854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tα1 treatment (1.6 mg subcutaneous injection for 15 days)
Number of subjects: 127
Study 33160854 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated, regular supportive treatment)
Number of subjects: 127
Study 32898435 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 W/LSI 4
Number of subjects: 80
Study 32898435 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 W/LSI 5
Number of subjects: 80
Study 32898435 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 W/LSI 4
Number of subjects: 80
Study 32898435 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 W/LSI 5
Number of subjects: 80
Study 35961801 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education (HE) + Progressive Muscle Relaxation (PMR)
Number of subjects: 108
Study 35961801 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 108
Study 35961801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 32993359 — intervention group
Group type: EXPERIMENTAL
Intervention: Court-type Thai traditional massage
Number of subjects: 40
Study 32993359 — intervention group
Group type: COMPARATOR
Intervention: Senokot treatment
Number of subjects: 40
Study 33089621 — intervention group
Group type: EXPERIMENTAL
Intervention: BaSO4 ‐ and Bi2 O3 ‐containing White MTA Angelus
Number of subjects: 36
Study 33089621 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 36
Study 33089621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi2 O3 ‐containing white Portland cement
Number of subjects: 36
Study 33089621 — intervention group
Group type: COMPARATOR
Intervention: Negative control (lateral wall of the tubes)
Number of subjects: 36
Study 35688662 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel
Number of subjects: 150
Study 35688662 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 150
Study 35688662 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel (in patients previously treated with abiraterone and/or enzalutamide)
Number of subjects: 150
Study 35688662 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in patients previously treated with abiraterone and/or enzalutamide)
Number of subjects: 150
Study 35688662 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel (in abiraterone/enzalutamide-naïve patients)
Number of subjects: 150
Study 35688662 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in abiraterone/enzalutamide-naïve patients)
Number of subjects: 150
Study 33706002 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitline-Coaching (eight weekly nutritionist-delivered coaching calls with workbook)
Number of subjects: 494
Study 33706002 — intervention group
Group type: COMPARATOR
Intervention: Fitline-Workbook (same workbook in eight mailings without coaching)
Number of subjects: 494
Study 32072071 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 90
Study 32072071 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg
Number of subjects: 90
Study 32072071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35022730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (3 g, 2 g ceftolozane/1 g tazobactam q8h)
Number of subjects: 511
Study 35022730 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g q8h)
Number of subjects: 511
Study 33407763 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthetics during cardiopulmonary bypass
Number of subjects: 100
Study 35231769 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg EO-PGS
Number of subjects: 480
Study 35231769 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g/kg EO-PGS
Number of subjects: 480
Study 35231769 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg EO-PGS
Number of subjects: 480
Study 35231769 — intervention group
Group type: EXPERIMENTAL
Intervention: EO-PGS groups
Number of subjects: 480
Study 34874420 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (n=407)
Number of subjects: 1221
Study 34874420 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (n=407)
Number of subjects: 1221
Study 34874420 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=407)
Number of subjects: 1221
Study 35904640 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat packs (TP)
Number of subjects: 148
Study 35904640 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat packs (TP) placed by anesthesiologist (B2)
Number of subjects: 148
Study 35904640 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat packs (TP) placed by surgeon (B1)
Number of subjects: 148
Study 35904640 — intervention group
Group type: COMPARATOR
Intervention: No throat packs (Control group A)
Number of subjects: 148
Study 34194240 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome® (QP)
Number of subjects: 42
Study 34194240 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SC)
Number of subjects: 42
Study 32592736 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative care
Number of subjects: 1357
Study 35254752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) with fluocinolone-based triple cream
Number of subjects: 0
Study 35254752 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone-based triple cream alone
Number of subjects: 0
Study 34544117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastball EEG method for recognition memory assessment
Number of subjects: 60
Study 34544117 — intervention group
Group type: COMPARATOR
Intervention: Behavioural 2AFC task
Number of subjects: 60
Study 34544117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastball EEG method
Number of subjects: 60
Study 34106556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 80
Study 34106556 — intervention group
Group type: COMPARATOR
Intervention: Expectant care
Number of subjects: 80
Study 615918511 — intervention group
Group type: EXPERIMENTAL
Intervention: Action game training (first person shooter) for 10 hours
Number of subjects: 40
Study 615918511 — intervention group
Group type: COMPARATOR
Intervention: Computer-based card game (control group) for 10 hours
Number of subjects: 40
Study 34806244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine use only
Number of subjects: 161
Study 34806244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine and crack-cocaine use
Number of subjects: 161
Study 34806244 — intervention group
Group type: EXPERIMENTAL
Intervention: Party and play use (methamphetamine, gamma-hydroxybutyrate, amyl nitrites, erectile dysfunction drugs)
Number of subjects: 161
Study 34806244 — intervention group
Group type: EXPERIMENTAL
Intervention: High polysubstance use
Number of subjects: 161
Study 34806244 — intervention group
Group type: COMPARATOR
Intervention: Demographic and psychological factors
Number of subjects: 161
Study 33148766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 64
Study 34174212 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's liquid soap with pH 5.8 (experimental group)
Number of subjects: 204
Study 34174212 — intervention group
Group type: COMPARATOR
Intervention: Common liquid soap with pH 7.0 (control group)
Number of subjects: 204
Study 34174212 — intervention group
Group type: COMPARATOR
Intervention: Both groups (no soap used on forehead)
Number of subjects: 204
Study 32419092 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual bolus-tracking (MBT, n=25)
Number of subjects: 75
Study 32419092 — intervention group
Group type: COMPARATOR
Intervention: Fixed delay time (FDT, n=25)
Number of subjects: 75
Study 32419092 — intervention group
Group type: COMPARATOR
Intervention: Automatic bolus-tracking (ABT, n=25)
Number of subjects: 75
Study 32419092 — intervention group
Group type: COMPARATOR
Intervention: Total effective dose (FDT)
Number of subjects: 75
Study 32419092 — intervention group
Group type: COMPARATOR
Intervention: Total effective dose (ABT)
Number of subjects: 75
Study 32419092 — intervention group
Group type: EXPERIMENTAL
Intervention: Total effective dose (MBT)
Number of subjects: 75
Study 32419092 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of total effective doses among groups A, B, and C
Number of subjects: 75
Study 36397128 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/daily)
Number of subjects: 95
Study 32067401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Appliance (OA)
Number of subjects: 17
Study 32067401 — intervention group
Group type: COMPARATOR
Intervention: No Oral Appliance (no OA)
Number of subjects: 17
Study 36695874 — intervention group
Group type: COMPARATOR
Intervention: Common standard arm 3 + 7 (CSA)
Number of subjects: 1286
Study 36695874 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group A (TAD/HAM versus HAM/HAM ± G‐CSF followed by TAD and maintenance)
Number of subjects: 1286
Study 36695874 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group B (intermediate‐dose ara‐C/mitoxantrone followed by ara‐C/mitoxantrone)
Number of subjects: 1286
Study 33611761 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate-based chemotherapy with rituximab
Number of subjects: 0
Study 33611761 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate-based chemotherapy without rituximab
Number of subjects: 0
Study 35044471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 916
Study 35044471 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 916
Study 35010917 — intervention group
Group type: EXPERIMENTAL
Intervention: CIT plus BR (3 g/kg/day of CIT plus 3 mg/kg/day of nitrates)
Number of subjects: 32
Study 35010917 — intervention group
Group type: COMPARATOR
Intervention: CIT (3 g/kg/day)
Number of subjects: 32
Study 35010917 — intervention group
Group type: COMPARATOR
Intervention: BR (3 mg/kg/day of NO3‐)
Number of subjects: 32
Study 35010917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLG)
Number of subjects: 32
Study 36434542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed meat puree
Number of subjects: 22
Study 36434542 — intervention group
Group type: COMPARATOR
Intervention: Control diet (unaltered freshly made pureed diets)
Number of subjects: 22
Study 34886337 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 6 weeks, performed thrice weekly (12‐16‐20 × 30‐s intervals interspersed with 1‐min rest periods)
Number of subjects: 19
Study 34886337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 19
Study 36045183 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy using an 830-nm LED device
Number of subjects: 43
Study 36045183 — intervention group
Group type: COMPARATOR
Intervention: Sham device without an LED
Number of subjects: 43
Study 35152127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine with Haloperidol
Number of subjects: 200
Study 35152127 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 200
Study 34917633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) 0.5 mg/kg, two times daily for 5 days
Number of subjects: 118